B
Bruce E. Johnson
Researcher at Harvard University
Publications - 523
Citations - 76494
Bruce E. Johnson is an academic researcher from Harvard University. The author has contributed to research in topics: Lung cancer & Cancer. The author has an hindex of 104, co-authored 474 publications receiving 68801 citations. Previous affiliations of Bruce E. Johnson include University of Adelaide & Virginia Tech.
Papers
More filters
Journal ArticleDOI
Outcome of patients with small-cell lung cancer: effect of changes in staging procedures and imaging technology on prognostic factors over 14 years.
Mary Pat Dearing,Seth M. Steinberg,Robert G. Phelps,Michael Anderson,James L. Mulshine,Daniel C. Ihde,Bruce E. Johnson +6 more
TL;DR: It is concluded that the sensitivity of the staging procedures used can affect the impact on survival of cancer involvement of a given site and patients with cancer confined to their chest with medical or anatomic contraindications to chest radiotherapy do not have a shorter survival than patients with limited-stage disease treated with chemotherapy alone.
Journal ArticleDOI
Impact of BRAF Mutation Class on Disease Characteristics and Clinical Outcomes in BRAF-mutant Lung Cancer.
Ibiayi Dagogo-Jack,Pablo Martinez,Beow Y. Yeap,Chiara Ambrogio,Lorin A. Ferris,Christine A. Lydon,Tom C. Nguyen,Nicholas A. Jessop,A. John Iafrate,Bruce E. Johnson,Jochen K. Lennerz,Alice T. Shaw,Mark M. Awad +12 more
TL;DR: BRAF-mutant NSCLC is a heterogeneous disease that encompasses 3 distinct functional classes that have more aggressive clinical features leading to less favorable outcomes and the distinct biological characteristics of class II and III tumors suggest that class-specific therapies may be necessary to effectively target these molecular subsets.
Journal ArticleDOI
Immunohistochemical markers associated with brain metastases in patients with nonsmall cell lung carcinoma.
Ali G. Saad,Beow Y. Yeap,Frederik B. Thunnissen,Geraldine S. Pinkus,Jack L. Pinkus,Massimo Loda,David J. Sugarbaker,Bruce E. Johnson,Bruce E. Johnson,Lucian R. Chirieac +9 more
TL;DR: Investigation of associations between immunohistochemical markers and the development of brain metastases in patients with NSCLC found no reliable markers able to identify patients with nonsmall cell lung cancer that will develop metastases to the brain.
Journal ArticleDOI
A multicenter effort to identify driver mutations and employ targeted therapy in patients with lung adenocarcinomas: The Lung Cancer Mutation Consortium (LCMC).
Bruce E. Johnson,Mark G. Kris,Lynne D. Berry,David J. Kwiatkowski,Anthony J. Iafrate,Marileila Varella-Garcia,Ignacio I. Wistuba,Wilbur A. Franklin,Marc Ladanyi,Pei Fang Su,Lecia V. Sequist,Fadlo R. Khuri,Edward B. Garon,William Pao,Charles M. Rudin,Joan H. Schiller,Eric B. Haura,Giuseppe Giaccone,John D. Minna,Paul A. Bunn +19 more
TL;DR: The detection of driver mutations in the EGFR and ALK genes and targeted therapy has transformed treatment of lung cancer and the LCMC was established to assay lung adenocarcinomas for driver genomic alterations in 10 genes and to study and treat patients by their molecular subtypes.
Journal ArticleDOI
PS01.05 Surgical and Clinical Outcomes With Neoadjuvant Atezolizumab in Resectable Stage IB–IIIB NSCLC: LCMC3 Trial Primary Analysis
Jivianne T. Lee,Jamie E. Chaft,Alan Nicholas,Alexander Patterson,S. Waqar,Eric M. Toloza,Eric B. Haura,Dan J. Raz,Karen L. Reckamp,Robert E. Merritt,Dwight H. Owen,David J. Finley,C. Mcnamee,Justin D. Blasberg,Edward B. Garon,John D. Mitchell,Robert C. Doebele,Frank A. Baciewicz,Misako Nagasaka,Harvey I. Pass,Katja Schulze,S. Phan,A. Johnson,Paul A. Bunn,Bruce E. Johnson,Mark G. Kris,David J. Kwiatkowski,I. I. Wistuba,David P. Carbone,V. Rusch +29 more